

Surgical Prophylactic Prescribing in African Hospitals. Findings from the Global-Point Prevalence Survey on Antimicrobial Consumption and Resistance (Global-PPS)



Contact: global-PPS@uantwerpen.be

Ann Versporten¹, Ines Pauwels¹, Annelies Boven¹, Erika Vlieghe^{1,3} ¹Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

ICAN 2025 Poster 187

BACKGROUND & AIMS

The Global-PPS (<u>www.global-pps.com</u>) monitors antimicrobial prescribing, healthcare associated infections and resistance in hospitals worldwide.

We analyzed a sub-group of patients who received an antibiotic for surgical prophylaxis (SP) in African hospitals.

Main aims:

- Determine the variation in quantity and quality of surgical prophylactic prescribing.
- Identify targets for quality improvement.





We examined Global-PPS data from 2015-2024

- 23 African countries
- ☐ 398 hospitals

METHODS

☐ 641 validated surveys

In-depth analyses for patients receiving SP at country level (indication code = SP)

Assessed quality indicators (QI)

- Choice of antibiotic
- Prolonged SP (> 1 day)
- Existence of guidelines
- Compliance to guidelines (choice of drug)

| | | | | KE5U |
|---------|--|------|------|------|
| | | | | |
| • • | | | | |

| Table 1. Antimicrobials for Africa in Global-PPS dataset (2015-2024) | N | % |
|--|--------|------|
| Antibacterials for systemic use (J01) | 71,938 | 86.8 |
| nitroimidazole derivatives (P01AB) | 3,977 | 4.8 |
| Antimalarials (P01) | 2,309 | 2.8 |
| Drugs for treatment of tuberculosis (J04A) | 1,724 | 2.1 |
| Antimycotics/antifungals for systemic use (J02 & D01BA) | 1,414 | 1.7 |
| Antivirals for systemic use (J05) | 1,155 | 1.4 |
| Antibiotics used as intestinal anti-infectives (A07AA) | 343 | 0.4 |
| | 82,860 | |
| | | 7 |

Selection on J01+P01AB+A07AA (76,258 prescriptions)



16,244 prescriptions (21.3%) for SP of which

- > 89.2% for age >17years
- **>** 10.8% for age ≤17 year

| Table 2. Top 5 diagnostic codes for SP in Africa* | % |
|---|------|
| Proph obstetric/gynaecology | 37.9 |
| Proph bone/joint | 29.2 |
| Proph gastrointestinal | 14.7 |
| Proph Central Nervous System | 4.9 |
| Proph Urinary Tract | 4.9 |

- * Diagnostic codes includes those for prophylactic & therapeutic use for indication=SP
- Top 3 antibiotics for SP: metronidazole (range: 5.8% in Tunisia to 41.7% in Uganda), ceftriaxone (range: 0% in Tunisia to 48.9% in Niger) and amoxicillin & enz. inh. (range: 0% in several countries to 57.5% in Tunisia) (Table 3).
 - > Metronidazole was mainly prescribed in combination with another antibiotic for obstetric/gynaecology or gastro-intestinal SP.
- Prolonged SP (>one day) was common (84.2%; range: 11.3% in Ivory Coast to 97.0% in Guinea).
- Local guidelines (referring to choice of drug) were lacking in 38.3% of all SP prescriptions and compliance to the type of antibiotic was 67.4%.

| | | COTE | | | | | | | SOUTH | | | | | | | |
|-----------------------|----------|----------|--------------|----------|---------------|---------|---------|-----------|-----------|----------|---------|---------|-----------|----------|-----------|-----------|
| | CAMEROON | D'IVOIRE | EGYPT | GHANA | GUINEA | KENYA | MALAWI | NIGERIA | AFRICA | TANZANIA | TOGO | TUNISIA | UGANDA | ZAMBIA 2 | ZIMBABWE | Total* |
| | (N=120) | (N=274) | (N=1,464) | (N=2093) | (N=365) | (N=579) | (N=690) | (N=6,564) | (N=1,116) | (N=700) | (N=184) | (N=154) | (N=1,100) | (N=291) | (N=229) (| N=16,244) |
| Metronidazole | 20.8 | 25.9 | 15.4 | 33.8 | 22.5 | 29.0 | 39.4 | 34.4 | 13.2 | 35.7 | 21.7 | 5.8 | 41.7 | 40.2 | 38.0 | 30.7 |
| Ceftriaxone | 15.8 | 36.1 | 19.9 | 7.8 | 27.9 | 33.5 | 43.8 | 20.7 | 4.5 | 36.4 | 28.3 | 0.0 | 38.6 | 30.2 | 15.7 | 21.6 |
| Amoxicillin/enz. inh. | 15.8 | 5.1 | 9.2 | 20.4 | 1.4 | 4.5 | 0.0 | 6.1 | 22.8 | 0.7 | 9.2 | 57.8 | 0.1 | 0.0 | 0.0. | 8.7 |
| Cefuroxime | 10.0 | 0.4 | 0.0 | 12.7 | 0.0 | 8.5 | 0.0 | 8.9 | 0.2 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 |
| Ciprofloxacin | 1.7 | 1.1 | 1.1 | 6.7 | 3.0 | 0.2 | 0.9 | 7.2 | 1.9 | 0.9 | 19.9 | 7.8 | 1.6 | 1.0 | 0.9 | 4.7 |
| Amoxicillin | 4.2 | 15.0 | 0.4 | 6.9 | 1.9 | 4.1 | 1.2 | 2.4 | 6.2 | 1.6 | 16.3 | 0.6 | 0.7 | 13.4 | 11.4 | 3.7 |
| Cefazolin | 9.2 | 0.0 | 1.8 | 0.0 | 0.0 | 4.1 | 0.0 | 0.0 | 36.8 | 1.1 | 0.0 | 2.6 | 0.9 | 0.0 | 0.0 | 3.1 |
| Gentamicin | 13.3 | 7.7 | 1.6 | 2.1 | 17.3 | 3.6 | 1.7 | 1.8 | 3.5 | 5.3 | 3.3 | 8.4 | 3.2 | 4.5 | 2.2 | 2.9 |
| Cefotaxime | 0.0 | 0.4 | 15.2 | 0.2 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 11.0 | 0.1 | 2.1 | 0.0 | 1.8 |
| Ampicillin | 1.7 | 0.0 | 1.7 | 0.1 | 21.9 | 0.0 | 1.3 | 0.2 | 4.1 | 2.7 | 0.5 | 0.0 | 2.4 | 0.0 | 0.4 | 1.6 |
| Benzylpenicillin | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 | 6.7 | 0.0 | 0.0 | 0.4 | 0.5 | 0.0 | 0.2 | 4.1 | 24.0 | 0.8 |

of antibiotics prescribed for SP across 15 African countries. **Countries with <100 SP** prescriptions (N=7) are not displayed but are included in the overall continental total. **Antibiotics accounting** for >10% of SP are highlighted in red.

Table 3. Proportion (%)

CONCLUSION

Various SP prescription practices have been observed in Africa, with a predominance of broad-spectrum antibiotics and a common tendency toward prolonged SP use. Further research is warranted due to the widespread use of broad-spectrum antibiotics for SP, particularly in relation to the relatively high rate of guideline-adherent prescribing.

Scan for more info on Global-PPS

